Printer Friendly

Eagle Pharmaceuticals awarded three new patents in the US for Bendeka.

M2 PHARMA-March 22, 2017-Eagle Pharmaceuticals awarded three new patents in the US for Bendeka

(C)2017 M2 COMMUNICATIONS

Pharmaceutical company Eagle Pharmaceuticals Inc (NasdaqGM:EGRX) revealed on Tuesday the receipt of three additional patents protecting Bendeka from the US Patent and Trademark Office (USPTO).

The company said the patent numbers, which has been subscribed 9,579,397 and 9,579,398 and 9,579,399, will expire March 2033.

In conjunction, the USPTO has now issued or allowed a total of 14 patents in the Bendeka family of patents expiring from 2026 to 2033, added the company.

These three newly issued patents will be listed in the US FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange-Book) bringing the company's total Orange Book listed patents for Bendeka to 13. Bendeka has received Orphan Drug Designation from the US FDA.

Pursuant to a 2015 exclusive license agreement, Teva Pharmaceutical Industries is responsible for all US commercial activities for Bendeka, including promotion and distribution.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 22, 2017
Words:173
Previous Article:Americans Have Substantial Differences in Drug-Metabolising Gene, Study Finds.
Next Article:Adaptimmune Therapeutics to offer ADSs in planned public offering.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters